Next Investors logo grey

MGC Pharmaceuticals achieves maiden cannabinoid production ahead of schedule


Published 10-APR-2017 15:33 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

European Union based specialist medical cannabis company, MGC Pharmaceuticals (ASX:MXC) has successfully commenced cannabinoid extraction operations at its newly completed European extraction facilities.

This has been achieved ahead of schedule, and today’s news comes less than a week after the company informed the market that construction of European CBD extraction facility had been completed on time and ahead of budget with first commercial production on schedule for the third quarter of 2017.

MXC’s shares responded strongly to the news, hitting a high of 8.1 cents in the first hour of trading, representing a 7% increase on the previous day’s close. More than half of the group’s average daily trading volumes went through in this period.

It should be noted share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

Commenting on this development, co-founder and Managing Director of MGC Pharmaceuticals, Nativ Segev said, “Producing the first cannabinoid extracts from our newly built European extraction facility is a significant milestone for the company, and in addition to demonstrating the operational success of the facility it marks the commencement of the next phase for our company where we are well-positioned to capture the value chain and generate revenues.”

This European extraction facility will produce high margin active pharmaceutical ingredients (API) cannabinoid extract for use in medical cannabis products, including MXC’s own clinical studies and trials in Europe and Australia.

The high quality cannabinoids CO2 extracts fractions depicted below confirm both the successful operational status of the facility, as well as its ability to produce high-quality extracts to be pipelined to the company’s various global projects.

Upcoming certification another potential share price catalyst

Commercial production of active pharmaceutical ingredients at the facility will commence once Good Manufacturing Practice (GMP) certification is achieved in the coming months.

Certification could be a share price catalyst, akin to a mining group receiving the appropriate permitting to commence operations.

MXC also confirmed that its Panax growing operations at the Institute of Experimental Botany (IEB) of the Academy of Sciences in the Czech Republic are continuing on schedule. The company owns 80% of Panax Pharma s.r.o. with the opportunity to acquire the remaining 20% should management choose to do so.

The following images are of seedlings of high quality medical cannabis strains that have been planted and grown at the IEB facility since mid-February 2017.

Next Investors Image

MXC will be planting up to 1000 square metres of cannabis plants in the Panax greenhouse facility with these crops expected to be harvested for research purposes in the third quarter of 2017.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.